Profil
Davey S.
Scoon is currently the Chairman of Virtus Investment Trust and a Director at Albireo AB and NCH Healthcare System, Inc. He previously served as the Chairman-Trustees Board of Virtus AllianzGI Dividend, Interest & Premium Strategy Fund, Vice Chairman-Trustees Board of Virtus Convertible & Income Fund, Virtus Equity & Convertible Income Fund, and Virtus Convertible & Income 2024 Target Term Fund.
He was also the Vice Chairman-Trustees Board of Virtus Artificial Intelligence & Technology Opportunities Fund.
Additionally, he served as an Independent Director at Orthofix Medical, Inc., NitroMed, Inc., Inotek Pharmaceuticals Corp., CardioKine, Inc., Biodel, Inc., AMAG Pharmaceuticals, Inc., and Albireo Pharma, Inc. He was the Chief Financial & Administrative Officer at Tom's of Maine, Inc., Sun Life Assurance Co. of Canada (U.S.), and Sun Life Financial (U.S.) Reinsurance Co. He was also the Chief Operating & Financial Officer at Liberty Funds Group, Inc. He received his undergraduate degree from the University of Wisconsin and his MBA from Harvard Business School.
Postes actifs de Davey Scoon
| Sociétés | Poste | Début |
|---|---|---|
Virtus Investment Trust
Virtus Investment Trust Investment Trusts/Mutual FundsMiscellaneous Acts as Open-End Investment Fund/Unit Trust | Président | 25/05/2009 |
Albireo AB
Albireo AB Pharmaceuticals: MajorHealth Technology Develops bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders | Directeur/Membre du Conseil | - |
NCH Healthcare System, Inc.
NCH Healthcare System, Inc. Electronic Equipment/InstrumentsElectronic Technology Provides healthcare systems and services | Directeur/Membre du Conseil | - |
Anciens postes connus de Davey Scoon
| Sociétés | Poste | Fin |
|---|---|---|
| ALBIREO PHARMA, INC. | Directeur/Membre du Conseil | 02/03/2023 |
| VIRTUS CONVERTIBLE & INCOME FUND | Président | 01/01/2019 |
| VIRTUS CONVERTIBLE & INCOME 2024 TARGET TERM FUND | Président | 01/10/2019 |
| VIRTUS DIVIDEND, INTEREST & PREMIUM STRATEGY FUND | Président | 31/12/2021 |
| VIRTUS EQUITY & CONVERTIBLE INCOME FUND | Directeur/Membre du Conseil | 31/12/2021 |
Formation de Davey Scoon
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 24 |
|---|---|
Orthofix Medical, Inc.
Orthofix Medical, Inc. Medical SpecialtiesHealth Technology Develops and markets surgical products to the spine & orthopedic markets | Health Technology |
NitroMed, Inc.
NitroMed, Inc. Pharmaceuticals: MajorHealth Technology Develops and supplies pharmaceuticals | Health Technology |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Engages in the development, discovery and commercialization of therapies for glaucoma and other diseases of the eye | Health Technology |
CardioKine, Inc.
CardioKine, Inc. Pharmaceuticals: MajorHealth Technology Develop drugs and pharmaceuticals for the treatment and prevention of heart failure | Health Technology |
Biodel, Inc.
Biodel, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Tom's of Maine, Inc.
Tom's of Maine, Inc. Household/Personal CareConsumer Non-Durables Manufactures and markets personal care products | Consumer Non-Durables |
Virtus AllianzGI Dividend Interest & Premium Strategy Fund
Virtus AllianzGI Dividend Interest & Premium Strategy Fund Investment Trusts/Mutual FundsMiscellaneous Acts as Closed-End Investment Fund/Investment Trust | Miscellaneous |
Virtus Diversified Income & Convertible Fund
Virtus Diversified Income & Convertible Fund Investment Trusts/Mutual FundsMiscellaneous Acts as Closed-End Investment Fund/Investment Trust | Miscellaneous |
Virtus Convertible & Income 2024 Target Term Fund
Virtus Convertible & Income 2024 Target Term Fund Investment Trusts/Mutual FundsMiscellaneous Acts as Closed-End Investment Fund/Investment Trust | Miscellaneous |
Virtus AllianzGI Artificial Intelligence & Technology Opps
Virtus AllianzGI Artificial Intelligence & Technology Opps Investment Trusts/Mutual FundsMiscellaneous Acts as Closed-End Investment Fund/Investment Trust | Miscellaneous |
Liberty Funds Group, Inc.
Liberty Funds Group, Inc. Investment ManagersFinance Liberty Funds Group focuses on the managed futures and commodities industry. Their Liberty Wealth Protection strategy is designed to protect the purchasing power of the US dollar. The strategy represents the firm's best ideas and cumulative experience and, like other managed futures vehicles, does not correlate to the performance of stock and bond markets. The strategy seeks to deliver outsized returns during periods of economic duress. In managing the strategy, Liberty Funds Group uses proprietary computerized multi-time scale mathematical models which trade on timeframes from a few hours to a year. These models trade a basket of futures and options markets and generate alpha from multiple, non-correlated sources such as trends, short-term mean reversion and expansion and option time decay. The trend following or directional component of the strategy is robust and adaptive. It allows for market behavior to establish time scales most suitable for capturing material price moves in a particular market. The directional component has a slight bias towards trades that would participate in rising commodity prices, rising interest rates and a weakening US dollar. The short term component considers tick data across multiple time frames from 4 days to 50 days to locate trading opportunities. The model looks for set ups that would tend to signal a break out from an area of price congestion. It also searches for an opportunity to profit from a trending market as it shows signs of reverting to a mean. The option component is built around two concepts: (1) trend following signals are false more often than they are true and (2) the time value of an option declines rapidly as it approaches expiration. Combining these concepts together with a futures based option defense strategy creates a unique stand-alone trading strategy. | Finance |
University of Wisconsin
University of Wisconsin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
NCH Healthcare System, Inc.
NCH Healthcare System, Inc. Electronic Equipment/InstrumentsElectronic Technology Provides healthcare systems and services | Electronic Technology |
Sun Life Assurance Co. of Canada (U.S.)
Sun Life Assurance Co. of Canada (U.S.) Life/Health InsuranceFinance Provides life insurance services | Finance |
Virtus Investment Trust
Virtus Investment Trust Investment Trusts/Mutual FundsMiscellaneous Acts as Open-End Investment Fund/Unit Trust | Miscellaneous |
AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Point32health Services, Inc.
Point32health Services, Inc. Life/Health InsuranceFinance Provides healthcare coverage services | Finance |
Albireo AB
Albireo AB Pharmaceuticals: MajorHealth Technology Develops bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders | Health Technology |
Virtus Convertible & Income Fund
Virtus Convertible & Income Fund Investment Trusts/Mutual FundsMiscellaneous Acts as Closed-End Investment Fund/Investment Trust | Miscellaneous |
Virtus Convertible & Income Fund II
Virtus Convertible & Income Fund II Investment Trusts/Mutual FundsMiscellaneous Acts as Closed-End Investment Fund/Investment Trust | Miscellaneous |
Virtus Equity & Convertible Income Fund
Virtus Equity & Convertible Income Fund Investment Trusts/Mutual FundsMiscellaneous Acts as Closed-End Investment Fund/Investment Trust | Miscellaneous |
Sun Life Financial (U.S.) Reinsurance Co. | |
Harvard Business School
Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Albireo Pharma, Inc.
Albireo Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets novel bile acid modulators for liver and gastrointestinal diseases and disorders | Health Technology |
















